» Articles » PMID: 1334964

M-CSF (monocyte Colony Stimulating Factor) and M-CSF Receptor Expression by Breast Tumour Cells: M-CSF Mediated Recruitment of Tumour Infiltrating Monocytes?

Overview
Journal J Cell Biochem
Date 1992 Dec 1
PMID 1334964
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Infiltrating immune cells in 30 primary human epithelial breast tumours were studied using specific anti-CD3 (T cells), anti-CD68 (macrophages), anti-CD57 (NK cells), and an anti-pan-B cell antibody (L26). The majority of tumour infiltrating inflammatory cells are T cells (40-50%) and monocytes/macrophages (15-35%). The macrophage specific chemo-attractant and growth factor CSF-1 is detected by immunohistochemical techniques (IHC) at the level of invasive breast cancer cells in 46/50 tumours but not at the level of in-situ (pre-invasive) cancer. A mosaic staining pattern was usually observed, with a very high expression in areas of obvious stromal invasion (90% cells positive) and absent or trace staining in intraductal carcinoma. Macrophages and plasma cells are equally intensely positive. In-situ hybridisation experiments confirm the production of CSF-1 (mRNA) by tumour cells and show the same pattern of expression. Expression of the CSF-1 receptor protein (fms) was also observed by IHC in 41/48 invasive tumours, albeit at weaker intensities than in tumour infiltrating monocytes/macrophages. A concomitant expression of both CSF-1 and fms in in-situ carcinoma was never seen (n = 14). It is therefore proposed that the associated expression of CSF-1 and its receptor may be linked to the invasive potential of breast cancer, the monocytic infiltrate being an indication of the quantitative importance of CSF-1 production by the tumour.

Citing Articles

The role of macrophage migratory behavior in development, homeostasis and tumor invasion.

Murrey M, Ng I, Pixley F Front Immunol. 2024; 15:1480084.

PMID: 39588367 PMC: 11586339. DOI: 10.3389/fimmu.2024.1480084.


A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.

Buchbinder E, Giobbie-Hurder A, Haq R, Ott P Invest New Drugs. 2023; 41(4):551-555.

PMID: 37247116 DOI: 10.1007/s10637-023-01374-3.


A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.

Buchbinder E, Giobbie-Hurder A, Ott P Invest New Drugs. 2023; 41(3):365-370.

PMID: 37097370 DOI: 10.1007/s10637-023-01364-5.


A timeline of tumour-associated macrophage biology.

Cassetta L, Pollard J Nat Rev Cancer. 2023; 23(4):238-257.

PMID: 36792751 DOI: 10.1038/s41568-022-00547-1.


Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes.

Komohara Y, Kurotaki D, Tsukamoto H, Miyasato Y, Yano H, Pan C Cancer Sci. 2023; 114(6):2220-2229.

PMID: 36748310 PMC: 10236637. DOI: 10.1111/cas.15751.